Why You Should Use a Toilet Paper Holder in Your Kitchen (It's So Cute!)
As a lifestyle editor, I'm constantly amazed by the brilliant hacks people discover for ordinary items — especially when they relate to some stylish organization. Whether it's using book bins as bathroom storage, lid organizers to store belts and hats, or lazy Susans to make stunning wall art, if there's a secret use for an item, someone on the internet is going to find it. And the latest trick I'm obsessed with can be used all over the home.
This Instagram Reel from couple Crystal and Scott Ransons, shows the most ingenious use for a toilet paper holder: as a cabinet vase! This antique-style gold holder would typically be used in the bathroom to hold toilet paper, but its open nature makes it the perfect vessel for a glass vase to hold flowers or other greenery. Plus, it's a superchic touch that'll match any kitchen style.
This design hack is just as easy to implement as it looks. Simply decide where you want it, screw your toilet paper holder into your wall or cabinet, and you've got a sleek storage addition in an instant. Aside from flowers, depending on how much weight it can hold, you might also use it to store a utensil crock, cooking oil, a small plant, or even a decorative faux candle.
Amazon
$32
Buy Now
If you want to get the look in your kitchen, this ornate brass toilet paper holder would make a gorgeous receptacle for the project. At about 4×5 inches, this gem is large enough to fit most narrow glass or ceramic vases, and its slats are close enough together to keep everything in place.
While the side of your kitchen cabinets is probably my favorite spot for this storage trick, it can really be used on any flat vertical surface. Put them on your living room wall, in your bedroom for plants or extra storage, or along your staircase to hold motion-sensor lights.
Buy: , $32.49This post originally appeared on Apartment Therapy. See it there: Why You Should Use a Toilet Paper Holder in Your Kitchen (It's So Cute!)
Why People Are Ditching Their Seltzer After a Disturbing Study
The One Cookware Brand That Gordon Ramsay Can't Stop Talking About
Le Creuset Launched a Pan That's Perfect for Everything from Stews to Stir-Fry — and It's Already on Sale
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
38 minutes ago
- Yahoo
HCA Healthcare Foundation Awards $1 Million Grant to Educate Texas for Healthcare Career Pathways
HCA Healthcare Inc. (NYSE:HCA) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 26, HCA Healthcare announced that its HCA Healthcare Foundation, through its Healthier Tomorrow Fund, will provide a new $1 million grant to Educate Texas, which is an initiative of Communities Foundation of Texas. HCA Healthcare Foundation promotes health and well-being across all the communities HCA Healthcare serves The latest donation expands upon a previous $1.35 million grant made by the Foundation to Educate Texas in 2022. The funding aims to increase student access to programs that prepare them for careers in healthcare, specifically focusing on high schools in Texas that offer Pathways in Technology Early College High School (P-TECH) healthcare career tracks. The initial 2022 grant supported the expansion of healthcare career pathways across P-TECH campuses, growing from 20 to 104 schools and enrolling ~10,000 high school students in these specialized programs. A team of healthcare professionals in lab coats and masks meeting at a hospital ward. The new $1 million grant will enable Educate Texas to further enhance the quality of program implementation. The initiative seeks to increase the number of students earning healthcare degrees and credentials and foster greater engagement of hospital employers, including HCA Healthcare-affiliated hospitals, with school districts in North Texas, Austin, San Antonio, and the Houston Gulf Coast region. HCA Healthcare Inc. (NYSE:HCA) owns and operates hospitals and related healthcare entities in the US. While we acknowledge the potential of HCA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
BioMarin's ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most undervalued US stocks according to analysts. On June 24, BioMarin Pharmaceutical Inc. presented new 5-year data from its Phase 3 GENEr8-1 trial at the 33rd Congress of the International Society on Thrombosis and Haemostasis/ISTH in Washington, D.C., which took place from June 21 to 25. The data reinforced the long-term efficacy and safety of ROCTAVIAN (valoctocogene roxaparvovec-rvox) as a gene therapy for severe hemophilia A. The GENEr8-1 trial is the longest and largest hemophilia gene therapy study to date, and demonstrated sustained Factor VIII (FVIII) expression and durable bleed control 5 years after a single treatment with ROCTAVIAN. A pharmaceutical plant manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide. FVIII activity remained consistent with previously reported results. Importantly, no new safety signals were observed over the 5-year study period. Across all 134 participants who received ROCTAVIAN in the study, there were no cases of FVIII inhibitors or thromboembolic events, and no treatment-related malignancies were observed. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology company that develops and commercializes therapies for life-threatening rare diseases and medical conditions internationally. While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
